Sacramento, CA (PRWEB) May 14, 2013
The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients who have taken the medication Byetta. The maker of the drug has agreed with moving the growing number of injury claims to a special federal court in California*.
DrugRisk was created to improve the safety of those taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Patients can see if others are experiencing similar side effects and decide if they need legal advice.
Byetta is a twice-daily injectable medication released in 2005 to help those with type-2 diabetes control blood sugar. It generated sales of over $300 million last year, when it was purchased with Amylin Pharmaceuticals by Bristol-Myers Squibb**.
However, DrugRisk has added a 2011 study from UCLA indicating Byetta could increase the risk of pancreatic cancer by 290% and thyroid cancer by 473%***. The Journal for the American Medical Association also recently warned these drugs can double the risk of pancreatitis, a major risk factor for pancreatic cancer****.
Due to the number of patients filing a Byetta lawsuit alleging cancer, lawyers have asked that cases be consolidated to a special federal multi-district court in California*****. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).
Now, DrugRisk has learned that Amylin and Eli Lilly have filed a response agreeing to the transfer to the federal court*. The resource center believes this could expedite the legal process for both the companies and patients alleging injury.
Anyone affected by cancer after taking Byetta is encouraged to speak with a lawyer about their legal options. However, due to the
Copyright©2012 Vocus, Inc.
All rights reserved